×
More Charts Below
Biosig Technologies Research and Development Expenses 2012-2024 | BSGM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Recent Trends
Biosig Technologies research and development expenses from 2012 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company Name
Market
Cap
Intuitive Surgical (ISRG)
$171.9B
Thermo Fisher Scientific (TMO)
$161.4B
Alcon (ALC)
$45.6B
Edwards Lifesciences (EW)
$42B
IDEXX Laboratories (IDXX)
$33.3B
DexCom (DXCM)
$26.9B
IQVIA Holdings (IQV)
$25.4B
STERIS (STE)
$21.8B
Mettler-Toledo (MTD)
$20.9B
Waters (WAT)
$19.1B
SONOVA HOLDING (SONVY)
$17.3B
Fresenius Medical Care AG KGaA (FMS)
$13.9B
Hologic (HOLX)
$12.9B
Sysmex ADR (SSMXY)
$11.8B
Penumbra (PEN)
$10.7B
Globus Medical (GMED)
$9.8B
Masimo (MASI)
$8.2B
Teleflex (TFX)
$6B
Glaukos (GKOS)
$5.2B
Integer Holdings (ITGR)
$4.1B
TransMedics (TMDX)
$3B
PROCEPT BioRobotics (PRCT)
$2.9B
Veracyte (VCYT)
$2.4B
Nihon Kohden (NHNKY)
$2.1B
LivaNova (LIVN)
$1.9B
Elekta AB (EKTAY)
$1.9B
Alphatec Holdings (ATEC)
$1.5B
Integra LifeSciences Holdings (IART)
$1.2B
Pulse Biosciences (PLSE)
$1.2B
Tandem Diabetes Care (TNDM)
$1.1B